Podcast: How Sandoz plans to harness its “golden decade”
At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap…
Features
The shrinking return on investment for Nordic innovation
Staunch biotech competition spurs new secretive tactics, shifts investor approach
Podcast: key readouts from ESC and ERS
Osaka has the science. Now it needs the business
Peptide innovator says the drug class is due for a rethink
MSD’s Lipfendra takes on injectable rivals for cholesterol-lowering market supremacy
MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones
